New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
17:07 EDTCELGCelgene study shows ABRAXANE improves survival for pancreatic cancer patients
Celgene International Sarl, a subsidiary of Celgene Corporation, announced that its phase III study of ABRAXANE, a paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-naive patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. The primary endpoint for the study is improvement in overall survival. Secondary endpoints include evaluation of progression-free survival, objective tumor response and the safety and tolerability of this combination in this patient population. The safety profile of ABRAXANE in combination with gemcitabine observed in the study is comparable with other ABRAXANE clinical trials in pancreatic cancer. Based on the results of the MPACT study, the company plans to submit dossiers for registration in the US, Europe and other markets. ABRAXANE is not currently approved for the treatment of advanced pancreatic cancer.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use